Buchmeier, EL, Reck, M, Girard, N, Nadal, E, Gay, CM, Filippi, AR, Martin, LW, Petersen, C, Cairns, DA, Roch, B, Attili, I, Alvarez, RA, Boyer, A, Tarruella, MM, Robinson, A, Levra, MG, Li, L, Perez, ID, Georgoulia, N, Spicer, J. Neoadjuvant (neoadj) durvalumab (D) plus chemotherapy (CT) followed by either surgery (Sx) and adjuvant D or CRT and consolidation D in patients (pts) with resectable or borderline resectable stage IIB-IIIB NSCLC: interim analysis (IA) of the phase 2 MDT-BRIDGE study. Oncology Research and Treatment. 2026; 49DOI:. PMID:. IF:1.600(Q4/9D).

Giani, C, Baldi, GG, Ljevar, S, Denu, RA, Andelkovic, V, Han, I, Brunello, A, Napolitano, A, Bhadri, VA, Scanferla, R, Garcia, AS, Abreu, MH, Campos, F, Ogura, K, Wong, DD, Bae, S, Marquina, G, Mazzocca, A, Yang, V, Nakazawa, MS, Kim, HS, Chiusole, B, Thway, K, Antonescu, C, Bellan, E, Bovée, JVMG, Davis, JL, Tos, APD, Di Blasi, E, Lazar, AJ, Sbaraglia, M, Schaefer, IM, Taverna, S, Chen, TWW, Miceli, R, Gronchi, A, Stacchiotti, S. International multicenter retrospective study on pleomorphic rhabdomyosarcoma (P-RMS), a PUSH platform study: outcome of primary localized disease. ESMO Open. 2026; 11(2)DOI:10.1016/j.esmoop.2025.106044. PMID:41564817. IF:8.300(Q1/2D).

Christoph, D, Paz-Ares, L, Borghaei, H, Liu, S, Peters, S, Herbst, R, Stencel, K, Tarruella, MM, Czyzewicz, G, Caro, RB, Lee, KH, Johnson, ML, Karadurmus, N, Grohé, C, Cuchelkar, V, Graupner, V, Kaul, M, Lin, YC, Chakrabarti, D, Bhatt, K, Reck, M. IMforte: Results from a Phase 3 study of first-line (1L) maintenance treatment (tx) with lurbinectedin (lurbi) plus atezolizumab (atezo) vs atezo in patients (pts) with ES-SCLC. Oncology Research and Treatment. 2026; 49DOI:. PMID:. IF:1.600(Q4/9D).

López-Tarruella, S, Guerrero-Zotano, A, Antolín, S, Cruz, J, Martínez, P, Rodríguez, CA, Falo, C, Rodríguez-Lescure, A, Adrover, E, Hernández, M, Andrés, R, Chacón, JI, Romero, JLA, Miguel, A, Gómez-Raposo, C, Margelí, M, González, I, Guerra, JA, Antón, A, Tibau, A, Miralles, JJ, Escudero, MJ, Bezares, S, Rojo, F, Alvarez, I. Clinical subtypes in breast cancer patients with brain metastases from an ambispective registry of advanced breast cancer, GEICAM/2014-03 (RegistEM). Therapeutic Advances in Medical Oncology. 2026; 18DOI:10.1177/17588359261421813. PMID:41732657. IF:4.200(Q2/3D).

Capdevila, J, Paez, D, Villacampa, MM, Garcia-Alvarez, A, Aparicio, J, Pampols, M, Riesco-Martinez, MD, Polo, E, Ruiz-Casado, A, Castañon, C, Soriano, S, Hernando, J, Navalpotro, B, Armario, D, Villacampa, G, Horvath, E, Virgili, AC, Asiain, L, Giménez, A, Guillot, M. Atezolizumab plus tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal: TIRANUS (GEMCAD-2103) trial.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(2_SUPPL)DOI:10.1200/JCO.2026.44.2_suppl.11. PMID:. IF:41.900(Q1/1D).

Hayes, M, Nakajima, TE, Seecof, O, Majem, M, Chenji, S, Ashki, N, Ceccarelli, M, Van Cutsem, E. A phase 2 randomized, double-blind, placebo-controlled study to evaluate LY3537021 for the treatment of chemotherapy-induced nausea and vomiting in patients with malignant disease.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(2_SUPPL)DOI:10.1200/JCO.2026.44.2_suppl.TPS855. PMID:. IF:41.900(Q1/1D).